On September 29, 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 taking place October 23-27, 2026, in Madrid.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zoci is a novel, potential first-in-class antibody-drug conjugate (ADC), that targets Delta-like ligand 3 (DLL3), a validated therapeutic target that is overexpressed in SCLC and is generally associated with poor clinical outcomes. The Phase 1b/1c cohort of the global trial is exploring the safety and efficacy of zoci in combination with atezolizumab with or without carboplatin.
"We look forward to sharing results from this trial evaluating zoci as first-line therapy for small cell lung cancer, one of the most aggressive and lethal solid tumors," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "We continue to be encouraged by zoci’s potential best-in-class safety profile, coupled with compelling systemic and intracranial efficacy that support zoci monotherapy as a potential new standard of care in previously treated ES-SCLC, as well as a backbone ADC in first-line combination regimens, including those that reduce the burden of chemotherapy."
ESMO 2026 zoci poster details:
Title: ZL 1310 (DLL3 ADC) plus Atezolizumab ± Carboplatin in extensive-stage small cell lung cancer: Part 1b/1c results from Study ZL 1310-001
Session Title: SCLC
Date/Time: October 26, 2026; 12:00-12:45 CEST
Location: Poster Area – Hall 5
Poster Board Number: 3817P
Abstract Number: 1569
Details regarding the webcast and conference call are as follows:
Date/Time: Friday, October 23, 2026, at 5:00 a.m. PT / 8:00 a.m. ET / 8:00 p.m. HKT
Registration available at:
Webcast presentation (preferred): View Source
Dial-in: View Source
Presenters: Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab; Pedro Rocha, M.D., Ph.D, MSc, Medical Oncology Department, Vall d’Hebron University Hospital
(Press release, Zai Laboratory, SEP 29, 2026, View Source [SID1234671168])